The US FDA’s Center for Biologics Evaluation and Research had a slow 2018 by many regulatory metrics. CBER’s novel approval tally was one of the smallest in recent years, with a marked increase in average time to approval and few products qualifying for expedited review programs.
But the center was also quite actively laying the groundwork for new regulatory frameworks for regenerative medicine and new efforts...







